Citaro M Sustained Release Tablets 50/1000 mg (Sitagliptin Hydrochloride Hydrate, Metformin Hydrochloride)

Adult dose

The dosage is determined within the limits of a maximum daily dose of 100 mg of sitagliptin and 2000 mg of metformin, considering each patient's current therapy, efficacy, and tolerability. This medication should be taken with food once daily in the evening to reduce gastrointestinal side effects due to metformin, and the dosage should be gradually increased. Sustained-release tablets should be swallowed whole without splitting, crushing, dissolving, or chewing.

This medication contains sitagliptin and metformin, which are diabetes treatments that help control blood sugar. While using this medication, allergic reactions may occur, so if symptoms such as skin rashes, hives, or difficulty breathing appear, usage should be discontinued immediately and medical advice sought. There is also a risk of developing acute pancreatitis, which is inflammation of the pancreas; therefore, symptoms such as abdominal pain, nausea, or vomiting should be reported to medical personnel immediately. Patients with severe renal impairment or serious conditions such as heart failure, acute myocardial infarction, or sepsis should not use this medication and should also discontinue use before and after examinations using iodinated contrast media. This medication is not recommended for use in pregnant or nursing women, or children under 18 years of age, as its safety and efficacy have not been established. During treatment with this medication, rare but potentially fatal side effects such as lactic acidosis should be monitored, and if symptoms like muscle pain, difficulty breathing, weakness, or abdominal pain occur, immediate hospital care is necessary. Symptoms of hypoglycemia may also occur, so it is important to eat regularly and avoid excessive exercise or alcohol consumption. Particularly, elderly patients or those with deteriorating kidney function should undergo regular kidney function tests and, if necessary, dosage adjustments or discontinuation should be considered. This medication may interact with other hypoglycemic agents or drugs, so it is essential to inform healthcare providers of any current medications being used. In cases of planned surgery, severe infections, or dehydration, administration should be temporarily halted and restarted once the condition improves. Finally, regular blood sugar monitoring and blood tests to check kidney function and vitamin B12 levels are necessary during treatment.

Serious side effects

Hives, severe swelling (angioedema), anaphylaxis, severe skin reactions (Stevens-Johnson syndrome, exfoliative dermatitis, rash), acute pancreatitis, acute renal failure, severe and disabling arthralgia, bullous pemphigoid, elevated liver enzymes, thrombocytopenia, rhabdomyolysis, lactic acidosis, hypoglycemia, acute respiratory distress, difficulty breathing, vision disturbances, confusion, seizures, severe headache, paralysis, severe edema, urination issues

Mild side effects

• Diarrhea
• upper respiratory tract infection
• headache
• nausea
• vomiting
• abdominal pain
• nasopharyngitis
• constipation
• muscle pain
• limb pain

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance

Bright green, oval-shaped sustained release film-coated tablets with a convex surface on both sides

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle